Amgen Inc. – NASDAQ:AMGN
Amgen stock price today
$297.4
+34.75
+13.23%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 4 hours
Amgen stock price monthly change
-20.61%
month
Amgen stock price quarterly change
-20.61%
quarter
Amgen stock price yearly change
-8.33%
year
Amgen key metrics
Market Cap | 141.76B |
Enterprise value | 192.57B |
P/E | 33.34 |
EV/Sales | 5.93 |
EV/EBITDA | 14.75 |
Price/Sales | 4.35 |
Price/Book | 18.73 |
PEG ratio | 5.26 |
EPS | 7.03 |
Revenue | 29.48B |
EBITDA | 10.46B |
Income | 3.76B |
Revenue Q/Q | 21.14% |
Revenue Y/Y | 12.56% |
Profit margin | 13.04% |
Oper. margin | 18.85% |
Gross margin | 60.35% |
EBIT margin | 18.85% |
EBITDA margin | 35.49% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAmgen stock price history
Amgen stock forecast
Amgen financial statements
Average Price Target
$334.7
Potential upside: 12.54%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 6.98B | 1.37B | 19.74% |
|---|---|---|---|
| Sep 2023 | 6.90B | 1.73B | 25.06% |
| Dec 2023 | 8.19B | 767M | 9.36% |
| Mar 2024 | 7.39B | -113M | -1.53% |
| 2023-02-07 | 4.09 | 4.09 |
|---|
Paying a dividend greater than earnings.
3.42%
Yield TTM
| Payout ratio | 112.7% |
|---|
| 2019 | 2.41% |
|---|---|
| 2020 | 2.79% |
| 2021 | 3.13% |
| 2022 | 2.97% |
| 2023 | 2.96% |
| Jun 2023 | 90269000000 | 83.48B | 92.49% |
|---|---|---|---|
| Sep 2023 | 90534000000 | 82.87B | 91.54% |
| Dec 2023 | 97154000000 | 90.92B | 93.59% |
| Mar 2024 | 92980000000 | 87.95B | 94.6% |
| Jun 2023 | 4.10B | -211M | -1.21B |
|---|---|---|---|
| Sep 2023 | 2.76B | -262M | -2.00B |
| Dec 2023 | 538M | -27.08B | 2.75B |
| Mar 2024 | 689M | -217M | -1.70B |
Amgen alternative data
Amgen Social Media Accounts
What are followers?
+0.33%
month
| Aug 2023 | 32665 |
|---|---|
| Sep 2023 | 32771 |
+1.51%
month
| May 2025 | 28160 |
|---|---|
| Jul 2025 | 28935 |
| Aug 2025 | 29372 |
Amgen
| 21 May 2023 | 26 |
|---|---|
| 28 May 2023 | 24 |
| 4 Jun 2023 | 24 |
| 11 Jun 2023 | 40 |
| 18 Jun 2023 | 30 |
| 25 Jun 2023 | 23 |
| 2 Jul 2023 | 26 |
| 9 Jul 2023 | 25 |
| 16 Jul 2023 | 25 |
| 23 Jul 2023 | 31 |
| 30 Jul 2023 | 24 |
| 6 Aug 2023 | 24 |
| 13 Aug 2023 | 24 |
| 20 Aug 2023 | 22 |
| 27 Aug 2023 | 26 |
| 3 Sep 2023 | 24 |
| 10 Sep 2023 | 20 |
| 17 Sep 2023 | 24 |
| 24 Sep 2023 | 23 |
| 1 Oct 2023 | 22 |
Amgen Top Products
| 19 Feb 2023 | 24 | 50 | 23 | 10 | 10 |
|---|---|---|---|---|---|
| 26 Feb 2023 | 21 | 46 | 14 | 9 | 10 |
| 5 Mar 2023 | 21 | 52 | 15 | 10 | 8 |
| 12 Mar 2023 | 20 | 51 | 15 | 8 | 9 |
| 19 Mar 2023 | 23 | 49 | 17 | 10 | 10 |
| 26 Mar 2023 | 20 | 52 | 19 | 9 | 9 |
| 2 Apr 2023 | 25 | 53 | 14 | 10 | 10 |
| 9 Apr 2023 | 23 | 50 | 17 | 9 | 10 |
| 16 Apr 2023 | 24 | 52 | 15 | 9 | 11 |
| 23 Apr 2023 | 20 | 55 | 14 | 10 | 10 |
| 30 Apr 2023 | 19 | 50 | 19 | 10 | 9 |
| 7 May 2023 | 20 | 57 | 20 | 9 | 9 |
| 14 May 2023 | 21 | 53 | 14 | 9 | 9 |
| 21 May 2023 | 19 | 50 | 13 | 8 | 8 |
| 28 May 2023 | 24 | 54 | 15 | 9 | 10 |
| 4 Jun 2023 | 24 | 56 | 21 | 11 | 8 |
| 11 Jun 2023 | 22 | 54 | 11 | 9 | 7 |
| 18 Jun 2023 | 22 | 60 | 16 | 10 | 11 |
| 25 Jun 2023 | 24 | 55 | 18 | 10 | 11 |
| 2 Jul 2023 | 22 | 60 | 19 | 9 | 13 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
What is job openings count?
| Aug 2023 | 380 |
|---|---|
| Sep 2023 | 532 |
| Oct 2023 | 478 |
| Nov 2023 | 198 |
| Dec 2023 | 610 |
| Jan 2024 | 536 |
| Feb 2024 | 506 |
| Apr 2024 | 629 |
| May 2024 | 582 |
| Jun 2024 | 974 |
| Jul 2024 | 838 |
| Aug 2023 | 25,200 |
|---|---|
| Sep 2023 | 25,200 |
| Oct 2023 | 25,200 |
| Nov 2023 | 25,200 |
| Dec 2023 | 25,200 |
| Jan 2024 | 25,200 |
| Feb 2024 | 25,200 |
| Mar 2024 | 26,700 |
| Apr 2024 | 26,700 |
| May 2024 | 26,700 |
| Jun 2024 | 26,700 |
| Jul 2024 | 26,700 |
Amgen other data
72.87%
-1.26%
of AMGN is owned by hedge funds
2.23K
+11
417.56M
-4.98M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 0 | 9558 |
| Sep 2023 | 1764705 | 0 |
| Nov 2023 | 0 | 10000 |
| Dec 2023 | 0 | 2096 |
| May 2024 | 0 | 2117 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | GRYGIEL NANCY A. officer: SVP & CCO | Common Stock | 2,117 | $313.09 | $662,801 | ||
Sale | GRYGIEL NANCY A. officer: SVP & CCO | Common Stock | 2,096 | $273.03 | $572,275 | ||
Sale | GRAHAM JONATHAN P officer: EVP, Gen. Counsel & Se.. | Common Stock | 10,000 | $272.81 | $2,728,140 | ||
Purchase | AMGEN INC 10 percent owner | Common Stock | 1,764,705 | $17 | $29,999,985 | ||
Sale | GORDON MURDO officer: EVP, Glo.. | Common Stock | 9,558 | $262.43 | $2,508,306 | ||
Sale | KHOSLA RACHNA officer: SVP, Business Developm.. | Common Stock | 387 | $292.9 | $113,352 | ||
Sale | GRYGIEL NANCY A. officer: SVP & CCO | Common Stock | 545 | $293.54 | $159,977 | ||
Sale | WILLIAMS R SANDERS director | Common Stock | 200 | $249.96 | $49,992 | ||
Sale | ECKERT ROBERT director | Common Stock | 6,600 | $249 | $1,643,380 | ||
Option | ECKERT ROBERT director | Nqso (Right to Buy) | 20,000 | $85.59 | $1,711,800 |
| Patent |
|---|
Grant Utility: Drug delivery device Filling date: 31 Jan 2020 Issue date: 13 Sep 2022 |
Grant Utility: Combination therapy including a KRAS.sup.G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers Filling date: 18 Nov 2019 Issue date: 13 Sep 2022 |
Application Filling date: 7 Mar 2022 Issue date: 8 Sep 2022 |
Application Filling date: 15 Feb 2022 Issue date: 8 Sep 2022 |
Application Filling date: 13 Oct 2021 Issue date: 8 Sep 2022 |
Application Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers Filling date: 9 Sep 2021 Issue date: 8 Sep 2022 |
Application Filling date: 3 Aug 2020 Issue date: 8 Sep 2022 |
Application Filling date: 24 Jul 2020 Issue date: 8 Sep 2022 |
Grant Filling date: 22 Nov 2021 Issue date: 6 Sep 2022 |
Grant Utility: Purification systems and methods Filling date: 6 Nov 2020 Issue date: 6 Sep 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 6 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 31 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 3 Aug 2023 | Q2 2023 Earnings Call Transcript |
Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More
Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns
Eli Lilly Comes Out As ADA Winner
Regeneron Pharmaceuticals: My Highest Conviction Pharma Pick For 2025
Amgen: A Defensive Biotech With Yield And Optionality
Regeneron Pharmaceuticals Stock May Be Worth Buying Again - Rating Upgrade
Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One
BeOne Medicines: Brukinsa Momentum And Pipeline Catalysts Justify Its Premium
Amgen: Imdelltra Data And Q1 Results Impress
-
What's the price of Amgen stock today?
One share of Amgen stock can currently be purchased for approximately $297.4.
-
When is Amgen's next earnings date?
Unfortunately, Amgen's (AMGN) next earnings date is currently unknown.
-
Does Amgen pay dividends?
Yes, Amgen pays dividends and its trailing 12-month yield is 3.43% with 113% payout ratio.It means that the company is paying a dividend greater than earnings. The last Amgen stock dividend of $1.94 was paid on 8 Mar 2022.
-
How much money does Amgen make?
Amgen has a market capitalization of 141.76B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 7.09% to 28.19B US dollars. Amgen earned 6.72B US dollars in net income (profit) last year or $4.09 on an earnings per share basis.
-
What is Amgen's stock symbol?
Amgen Inc. is traded on the NASDAQ under the ticker symbol "AMGN".
-
What is Amgen's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers - General industry.
-
How do i buy shares of Amgen?
Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Amgen's key executives?
Amgen's management team includes the following people:
- Mr. Robert A. Bradway Chairman, Chief Executive Officer & Pres(age: 62, pay: $5,730,000)
- Mr. Murdo Gordon Executive Vice President of Global Commercial Operations(age: 58, pay: $2,880,000)
- Dr. David M. Reese M.D. Executive Vice President of R&D(age: 62, pay: $2,710,000)
- Mr. Esteban Santos Executive Vice President of Operations(age: 57, pay: $2,590,000)
- Mr. Peter H. Griffith Executive Vice President & Chief Financial Officer(age: 66, pay: $2,570,000)
-
How many employees does Amgen have?
As Jul 2024, Amgen employs 26,700 workers.
-
When Amgen went public?
Amgen Inc. is publicly traded company for more then 42 years since IPO on 17 Jun 1983.
-
What is Amgen's official website?
The official website for Amgen is amgen.com.
-
Where are Amgen's headquarters?
Amgen is headquartered at One Amgen Center Drive, Thousand Oaks, CA.
-
How can i contact Amgen?
Amgen's mailing address is One Amgen Center Drive, Thousand Oaks, CA and company can be reached via phone at 805 447 1000.
-
What is Amgen stock forecast & price target?
Based on 9 Wall Street analysts` predicted price targets for Amgen in the last 12 months, the avarage price target is $334.7. The average price target represents a 12.54% change from the last price of $297.4.
Amgen company profile:
Amgen Inc.
amgen.comExchange:
NASDAQ
Full time employees:
26,700
Industry:
Drug Manufacturers - General
Sector:
Healthcare
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
Thousand Oaks, CA 91320-1799
CIK: 0000318154
ISIN: US0311621009
CUSIP: 031162100
